2025-12-28 - Analysis Report
Okay, let's break down the provided Johnson & Johnson (JNJ) data and provide a comprehensive analysis.

**0) Introduction**

This report analyzes the current state of Johnson & Johnson (JNJ) stock, comparing it to the S&P 500 (VOO) and examining recent performance, news, analyst opinions, earnings, and financial data.

**1) Return Rate Comparison**

*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 60.02%
*   **VOO Cumulative Return:** 103.21%
*   **Divergence:** -41.8 (Relative Divergence: 28.9)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period considered.  The -41.8 divergence indicates substantial underperformance. The relative divergence of 28.9 suggests that the current underperformance is relatively close to the worst end of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2015-2017  | 26.0%  | 66.8%  | -2.0%  | -0.1  | 336.6  |
| 2016-2018  | 14.0%  | 10.7%  | -1.0%  | 0.1   | 310.9  |
| 2017-2019  | 20.0%  | 71.5%  | -2.0%  | 0.4   | 351.4  |
| 2018-2020  | 19.0%  | 79.2%  | -4.0%  | 0.4   | 379.2  |
| 2019-2021  | 33.0%  | 79.2%  | -14.0% | 0.5   | 412.2  |
| 2020-2022  | 8.0%   | 79.6%  | 9.0%   | 0.4   | 425.6  |
| 2021-2023  | -19.0% | 79.6%  | -20.0% | 0.3   | 377.6  |
| 2022-2024  | -32.0% | 79.6%  | -53.0% | 0.3   | 348.4  |
| 2023-2025  | 31.0%  | 79.6%  | -37.0% | 0.1   | 500.2  |

*   **CAGR:**  Varies significantly, showing periods of strong growth and recent declines.
*   **MDD:**  High Maximum Drawdown (MDD) figures across all periods indicate significant risk of loss, despite the company's reputation as a stable stock.
*   **Alpha:**  Mostly negative alpha suggests underperformance relative to its risk-adjusted expected return, especially in recent years.  The large negative Alpha values in 2019-2021, 2021-2023, 2022-2024 and 2023-2025 are concerning.
*   **Beta:**  Beta values generally between 0.1 and 0.5 indicates the stock is less volatile than the overall market.
*   **Cap(B):** Market capitalization has generally increased over time, although it has fluctuated.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 207.63
*   **Previous Close:** 207.78
*   **Change:** -0.07
*   **5-day SMA:** 206.976
*   **20-day SMA:** 206.6775
*   **60-day SMA:** 197.4092

**Analysis:**  The stock price is currently slightly down. The 5-day and 20-day SMAs are close to the current price, suggesting limited short-term momentum. The 60-day SMA being significantly lower indicates that the stock has been trending upwards over the past two months.

**3) RSI, PPO, and Expected Return**

*   **MRI:** 1.0 (High Investment Recommended)
*   **RSI:** 59.29 (Approaching Overbought)
*   **PPO:** -0.3387
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2025-12-03)
*   **Recent Relative Divergence Change:** -5.1 (Short-term Decline)
*   **Expected Return:** -59.0%

**Analysis:**

*   **MRI:** Despite other concerning indicators, the Market Risk Indicator surprisingly suggests a high investment recommendation.
*   **RSI:**  The RSI suggests the stock is nearing overbought territory, which could indicate a potential pullback.
*   **PPO:** The negative PPO suggests the stock's short-term moving average is below its long-term moving average, indicating a downward trend.
*   **Hybrid Signal:** Suggests a "Buy" signal, indicating potential for future appreciation.
*   **Relative Divergence:**  The recent decrease indicates short-term underperformance relative to the S&P 500.
*   **Expected Return:** A deeply negative expected return (-59.0%) is a significant red flag. It suggests that, based on the models used, the stock is projected to significantly underperform the S&P 500 over the long term.

**4) Recent News & Significant Events**

*   **Eczema Drug Trial Halt:** Negative news can impact stock prices.
*   **Stock Drops Despite Market Gains:**  This reinforces the underperformance concern.
*   **Talc Verdict, Drug-Price Pressure, Q4 Earnings:**  Indicates ongoing headwinds. The Talc verdict indicates legal challenges which will create a financial burden in the future.
*   **Bar Harbor Wealth Management Sells Shares:**  Institutional selling can put downward pressure on the stock.
*   **Shares Surging This Month:**  A positive article, but needs to be considered in the context of other negative news and long term performance.
*   **JNJ Holds Near $207:** A short term snapshot of performance.

**Analysis:** The news is mixed, with some positive articles but also concerns about trial halts, underperformance, talc litigation, and institutional selling.  The balance seems tilted towards negative catalysts.

**4-2) Analyst Opinions**

*   **Consensus:**  Buy (2.16)
*   **Target Price:** 209.29 (Avg) / 240.00 (High) / 155.00 (Low)
*   **Recent Rating Changes:**  No recent changes provided.

**Analysis:** Analysts generally have a "Buy" rating on the stock. The average target price is slightly above the current price, suggesting potential upside.  However, the wide range between the high and low target prices reflects considerable uncertainty among analysts.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-10-22 | 2.14 | 23.99 B$  |
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2025-10-22 | 1.12 | 22.47 B$  |

**Analysis:** The provided data contains duplicate values for 2025-10-22. The EPS has fluctuated significantly.  Revenue has been relatively stable, with a recent increase.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2025-09-30 | $23.99B     | 69.56%        |
| 2025-06-30 | $23.74B     | 67.87%        |
| 2025-03-31 | $21.89B     | 66.40%        |
| 2024-12-31 | $22.52B     | 68.35%        |
| 2024-09-30 | $22.47B     | 69.01%        |

**Capital and Profitability:**

| Quarter    | Equity      | ROE    |
|------------|-------------|--------|
| 2025-09-30 | $79.28B     | 6.50%  |
| 2025-06-30 | $78.47B     | 7.06%  |
| 2025-03-31 | $78.11B     | 14.08% |
| 2024-12-31 | $71.49B     | 4.80%  |
| 2024-09-30 | $70.16B     | 3.84%  |

**Analysis:** Revenue has shown a modest increasing trend. Profit margins are very high, indicating strong pricing power and efficient operations.  Equity has been growing. ROE has been volatile, with a large spike in 2025-03-31, suggesting potential fluctuations in profitability relative to shareholder equity.

**7) Comprehensive Analysis**

Johnson & Johnson (JNJ) presents a mixed picture. While it has a reputation as a stable, blue-chip stock, the data reveals several concerning trends:

*   **Underperformance:**  It has significantly underperformed the S&P 500.
*   **Negative Alpha:**  Suggests the stock isn't delivering expected returns given its risk.
*   **High MDD:** High Maximum Drawdown (MDD) figures across all periods indicate significant risk of loss, despite the company's reputation as a stable stock.
*   **Negative Expected Return:**  The most concerning signal.
*   **Mixed News:**  Negative catalysts related to drug trials, litigation, and sales.
*   **Volatile ROE:** The ROE has been volatile.
*   **Analyst Buy Rating:** The MRI shows high investment recommendation as well as analysts have a buy rating, but the target price range is wide, reflecting uncertainty.

**Conclusion:** While JNJ possesses strong financials and a dominant position in its industry, the negative expected return, underperformance relative to the S&P 500, and negative news flow warrant caution. Potential investors should carefully weigh these risks against the company's perceived stability and analyst recommendations. The extremely negative expected return is difficult to ignore and should be investigated further.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.